Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:24 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
NCT03654755 · Asana BioSciences · PHASE2 · terminated · last registry update 2023-09-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Phase 2 study results” | – | Registry record, Asana BioSciences |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against JAK3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-08-23Results posted on the registry: Incyte Corporation, parsaclisib + ruxolitinib (NCT04551053)
- 2024-08-12Phase 3 first posted: Incyte Corporation, Ruxolitinib Cream + Vehicle Cream (NCT06548360)
- 2024-07-30Results posted on the registry: Children's Hospital Medical Center, Cincinnati, Tofacitinib (NCT03288324)
- 2024-06-28Phase 3 first posted: Kartos Therapeutics, Inc., Navtemadlin + Navtemadlin placebo (NCT06479135)
- 2024-06-17Phase 3 first posted: AbbVie, Upadacitinib + Dupilumab (NCT06461897)
- 2024-04-29Phase 3 first posted: AbbVie, Upadacitinib 15mg Dose + Dupilumab 300mg Dose (NCT06389136)
- 2024-04-18Results posted on the registry: Dana-Farber Cancer Institute, Ruxolitinib + Paclitaxel (NCT02876302)
- 2024-03-27Phase 3 first posted: AbbVie, Upadacitinib (NCT06332534)
- 2024-03-05Results posted on the registry: Fred Hutchinson Cancer Center, Busulfan + Cyclophosphamide (NCT02251821)
- 2024-02-02Phase 3 first posted: Incyte Corporation, Ruxolitinib Cream + Vehicle Cream (NCT06238817)
- 2024-01-30Results posted on the registry: Celgene, FEDRATINIB + Best Available Therapy (BAT) (NCT03952039)
- 2024-01-29Phase 3 first posted: Takeda, Vedolizumab + Upadacitinib (NCT06227910)
- 2023-12-15Phase 3 first posted: Zhejiang University, Prednisone+Tofacitinib + Prednisone (NCT06172361)
- 2023-12-08Phase 3 first posted: Pfizer, Ritlecitinib + Ritlecitinib 100 mg (NCT06163326)
- 2023-12-07Results posted on the registry: Incyte Corporation, Ruxolitinib cream + Vehicle Cream (NCT04896385)
- 2023-11-07Phase 3 first posted: AbbVie, Upadacitinib + Placebo (NCT06118411)
- 2023-10-17Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Ruxolitinib (NCT03722407)
- 2023-10-12Phase 3 first posted: Merck Sharp & Dohme LLC, Bomedemstat + Anagrelide (NCT06079879)
- 2023-10-10Phase 3 first posted: Pfizer, Ritlecitinib + Ritlecitinib (NCT06072183)
- 2023-08-31Phase 3 first posted: Hangzhou Highlightll Pharmaceutical Co., Ltd, TLL-018 + Tofacitinib (NCT06020144)
- 2023-08-25Phase 3 first posted: AbbVie, Upadacitinib + Placebo (NCT06012240)
- 2023-08-22Phase 3 first posted: LEO Pharma, Delgocitinib (NCT06004050)
- 2023-07-19Results posted on the registry: Incyte Corporation, ruxolitinib + Vehicle (NCT04530344)
- 2023-06-05Phase 3 first posted: AbbVie, Upadacitinib + Placebo (NCT05889182)
- 2023-05-06Phase 3 first posted: AbbVie, Upadacitinib + Placebo (NCT05843643)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision